Work

Similar Efficacy in Belatacept-Converted Kidney Transplant Recipients With Steroid-Avoiding Regimen

Year: 2024

Type: article

Abstract: Introduction: Belatacept offers a valuable alternative to calcineurin inhibitors (CNIs) for reducing toxicity in kidney transplant recipients (KTRs). No study has evaluated the efficacy and safety of late-conversion belatacept with steroid avoidance in KTRs. Methods: This retrospective multicentric study evaluated the efficacy and safety of a belatacept-based steroid-avoiding therapy, in comparison with concomitant steroid use. The study included KTRs from 4-French transplant centers who were converted to belatacept at least 6 months posttransplantation. Results: < 0.001). Conclusion: Avoiding steroids in KTRs who are late-converted to belatacept is associated with a similar efficacy along with lower mortality and reduced incidence of severe infections in selected low-sensitized patients.

Source: Kidney International Reports

DOI: 10.1016/j.ekir.2024.12.019